Democratic Republic of Congo (DRC)
-
WHO recommends two new Bundibugyo Ebola vaccine candidates for DRC trial
The candidates are ChAdOx1, developed by the University of Oxford in partnership with the Serum Institute of India, and Moderna’s mRNA-1469.
-
MONUSCO donates Ebola prevention equipment to Congolese police in Bunia
The donation includes 500 FFP2/N95 protective masks, 20 infrared thermometers for temperature screening, 100 units of alcohol-based hand sanitiser, 125 units of disinfectant liquid soap and 10 handwashing stations, each with a 100-litre capacity.
-
WHO deploys AI-powered epidemic intelligence platform in DRC amid Ebola response
The DRC is the first country to adopt PDX, which connects national teams to a regional intelligence system serving all 47 Member States in the WHO African Region.
-
Roche Diagnostics supplies testing equipment to support Ebola response in DRC
Roche will configure the LightCycler and MagNA Pure systems before local laboratory technicians receive training and deploy the equipment to Bunia for validation testing.
-
WHO allocates 20,000 Ervebo doses for Ebola trial in DRC
The allocation forms part of an initial release of 70,000 Ervebo doses to the Democratic Republic of the Congo (DRC).
-
DRC launches 180-Day Plan to intensify response to Ebola outbreak
As of September 2, the outbreak had recorded 6,342 cases and 3,072 deaths, making it the second largest Ebola outbreak ever reported in the country and the fastest growing to date.
-
DRC secures 70,000 Ervebo vaccine doses for Bundibugyo virus outbreak
The ICG will allocate 20,000 doses to a Phase 3 clinical trial designed to assess whether Ervebo can protect people against Bundibugyo virus.
-
Africa CDC endorses scientific expert recommendations for DRC Ebola outbreak
Following a review of the latest epidemiological data, the ECG noted that the DRC had recorded 4,449 confirmed Ebola cases and 2,061 confirmed deaths, representing a case-fatality rate of 46.3%.
-
WHO launches EBO-PEP trial to test Obeldesivir for preventing Bundibugyo Ebola outbreak
The EBO-PEP platform trial, which has been under development since 2024, will evaluate several medicines as post-exposure prophylaxis for people who have had high-risk contact with filoviruses, the virus family that includes Bundibugyo Ebola.
-
WHO grants first emergency use listing for Bundibugyo Ebola diagnostic test
The test detects the virus by identifying its genetic material in blood samples, allowing health workers to confirm infections quickly and accurately.